Paul Mampilly is a senior editor at Banyan Hill Publishing where he writes articles to help many Americans find wealth in growth investing, small-cap stocks, special investment opportunities, and technology. Paul started as an assistant portfolio manager at Bankers Trust on Wall Street in 1991. In 2006, Paul was then recruited by a firm named Kinetics Asset Management, which had an asset of $6 billion, to manage their hedge funds. Under Paul expert supervision, he assisted in increasing the hedge funds assets to $25 billion. Barron’s named this phenomenon one of the “World’s Best” hedge funds because it averaged an annual return of 26% during Paul Mampilly’s tenure.
According to Paul Mampilly was also able to generate a 76% return in two years from an original investment of $50 million despite the 2008 and 2009 financial crisis. Tired of helping the 1% grow richer, he retired to help the everyday American grow in wealth. Paul Mampilly now has 90,000 readers following his financial advise on investment. In April of 2018, Paul Mampilly, again, gave advice for precision medicine. He believes that the company that leads this revolution will have a great impact on the healthcare industry. Paul seems to have found a company in the Midwest that may have potential in leading this trend in the market.
Precision medicine is specifically designed for the individual that it is prescribed to. This can possibly be done through examination of the person’s DNA and coming up with a solution to a problem or preventing a disease based on how the individual’s body functions as indicated by their DNA. If this can be accomplished then diseases such as Alzheimer disease, arthritis, heart disease, and Parkinson’s disease can be eradicated. Paul Mampilly indicated the $1.5 billion company Myriad Genetics which is doing research on this medical approach. Myriad Genetics is a diagnostic company that test and assesses a person’s risk for cancer. Their stock began rising in August of 2017, which was when Paul started suggesting this stock. Currently, they are the leader in precision medicine research as they search for cancer variant data and mutations.